Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.

Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N.

Hepatology. 2012 Jan;55(1):20-9. doi: 10.1002/hep.24623. Epub 2011 Nov 29.

PMID:
21898478
2.

Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.

Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Tasaka M, Sakamoto N, Miyake S.

Gastroenterology. 2008 May;134(5):1396-405. doi: 10.1053/j.gastro.2008.02.019. Epub 2008 Feb 14.

PMID:
18471516
3.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
4.

Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.

Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Kitabatake S, Murakami Y.

Cytokine. 2013 Aug;63(2):145-50. doi: 10.1016/j.cyto.2013.04.012. Epub 2013 May 11.

PMID:
23673288
5.

Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.

Benito JM, García-Samaniego J, García M, Madejón A, Martín-Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N.

J Interferon Cytokine Res. 2017 Jun;37(6):278-286. doi: 10.1089/jir.2016.0078. Epub 2017 Apr 25.

PMID:
28440692
6.

IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.

Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, Touscoz GA, Rizzetto M, Pellicano R, Smedile A.

World J Gastroenterol. 2014 Sep 28;20(36):13146-52. doi: 10.3748/wjg.v20.i36.13146.

7.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

8.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

9.

Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.

Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, Yeon JE, Kwon OS, Kim YS, Choi DJ, Kim JH, Byun KS.

J Clin Gastroenterol. 2013 Aug;47(7):644-50. doi: 10.1097/MCG.0b013e3182896abf.

PMID:
23442843
10.

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, Misael U, Méndez-Sánchez N.

Ann Hepatol. 2012 Nov-Dec;11(6):876-81.

11.

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K.

J Viral Hepat. 2011 Jul;18(7):e325-31. doi: 10.1111/j.1365-2893.2010.01425.x. Epub 2011 Jan 13.

PMID:
21692944
12.

Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.

Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A.

Arch Virol. 2015 Aug;160(8):2009-17. doi: 10.1007/s00705-015-2482-3. Epub 2015 Jun 10.

PMID:
26060059
13.

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.

Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, Shim JH, Kim KM, Lee HC, Lee YS, Suh DJ.

Clin Mol Hepatol. 2014 Jun;20(2):177-84. doi: 10.3350/cmh.2014.20.2.177. Epub 2014 Jun 30.

14.

Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.

Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Treeprasertsuk S, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P.

PLoS One. 2015 Sep 4;10(9):e0137365. doi: 10.1371/journal.pone.0137365. eCollection 2015.

15.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

16.

Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.

Vasconcelos LR, Moura P, do Carmo RF, Pereira LB, Cavalcanti Mdo S, Aroucha DC, Dutra RA, Pereira LM.

Hum Immunol. 2014 Aug;75(8):895-900. doi: 10.1016/j.humimm.2014.06.017. Epub 2014 Jun 30.

PMID:
24994464
17.

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S; Hokuriku Liver Study Group.

Gastroenterology. 2010 Aug;139(2):499-509. doi: 10.1053/j.gastro.2010.04.049. Epub 2010 Apr 29.

PMID:
20434452
18.

High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.

Fateh A, Aghasadeghi MR, Keyvani H, Mollaie HR, Yari S, Hadizade Tasbiti AR, Ghazanfari M, Monavari SH.

Asian Pac J Cancer Prev. 2015;16(5):1873-80.

19.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.

J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x.

PMID:
22432893
20.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.

Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.

PMID:
21068134

Supplemental Content

Support Center